Ranitidine’s return 'unlikely to provide greater clinical benefit'
New formulation incorporates stronger manufacturing controls and stability measures to prevent a possible carcinogen from forming.
-
12/03/2025
-
by Doug Brunk
The FDA recently approved a newly reformulated ranitidine tablet, allowing the H2 receptor blocker to return to the U.S. market after 5 years. The previous version was removed in 2020 because N-nitrosodimethylamine (NDMA), a potential carcinogen, could form in the product over time. The new formulation incorporates stronger manufacturing controls and stability measures to prevent NDMA from forming during storage.
Ranitidine has been used to treat GERD, peptic ulcers, and conditions with excess acid production such as Zollinger–Ellison syndrome. The FDA reported that the reformulated product works the same as earlier approved versions and offers the same expected clinical benefit.
According to Binu V. John, MD, a spokesperson for the American Gastroenterological Association and Chief of Gastroenterology and Hepatology at the Miami VA Health System, since the withdrawal of ranitidine, most patients were switched over to famotidine, a medication with an identical mechanism of action and without similar concerns.
“Famotidine at doses of 20 mg is equivalent in potency to the clinically recommended dose of 150 mg of ranitidine,” Dr. John said. “Additionally, famotidine has a longer half-life, and unlike ranitidine, does not have drug interactions with medications metabolized by the P450 enzymes. Therefore, the availability of ranitidine back in the market is unlikely to provide a greater clinical benefit over current options.”
The FDA recommends that any switch to ranitidine from another medication should be guided by the patient’s current symptom control, risk factors, and overall treatment plan. The new formulation also comes with updated storage instructions, which are important for keeping the product stable and preventing NDMA formation.
To maintain safety and product quality, the FDA highlighted several key steps that patients and clinicians should follow:
Keep ranitidine tablets in the original bottle and protect the bottle from moisture.
After opening the bottle for the first time, discard any remaining tablets after 90 days, or by the expiration date—whichever comes first.
If multiple bottles are dispensed, open only one at a time; keep the others sealed until needed.
Remove just one tablet per dose and secure the bottle immediately.
Do not remove the desiccant; it must stay in the bottle.
“While it is beneficial to have an alternative drug available for patients, both medications work by the same mechanism and ranitidine does not offer advantages over famotidine,” Dr. John said. “The major downside of medications in this class is tachyphylaxis, where these medications lose potency after 6 to 8 weeks of use. Unfortunately, this limitation applies to both drugs.”
Dr. John disclosed that he has received research support from Exact Sciences, Takeda, and Genentech, and has served as an advisor to Madrigal and Ipsen.
Summary content
7 Key Takeaways
-
1
Developed a paper-based colorimetric sensor array for chemical threat detection.
-
2
Can detect 12 chemical agents, including industrial toxins.
-
3
Production cost is under 20 cents per chip.
-
4
Utilizes dye-loaded silica particles on self-adhesive paper.
-
5
Provides rapid, simultaneous identification through image analysis.
-
6
Inspired by the mammalian olfactory system for pattern recognition.
-
7
Future developments include a machine learning-enabled reader device.
The guidelines emphasize four-hour gastric emptying studies over two-hour testing. How do you see this affecting diagnostic workflows in practice?
Dr. Staller: Moving to a four-hour solid-meal scintigraphy will actually simplify decision-making. The two-hour reads miss a meaningful proportion of delayed emptying; standardizing on four hours reduces false negatives and the “maybe gastroparesis” purgatory that leads to repeat testing. Practically, it means closer coordination with nuclear medicine (longer slots, consistent standardized meal), updating order sets to default to a four-hour protocol, and educating front-line teams so patients arrive appropriately prepped. The payoff is fewer equivocal studies and more confident treatment plans.
Metoclopramide and erythromycin are the only agents conditionally recommended for initial therapy. How does this align with what is being currently prescribed?
Dr. Staller: This largely mirrors real-world practice. Metoclopramide remains the only FDA-approved prokinetic for gastroparesis, and short “pulsed” erythromycin courses are familiar to many of us—recognizing tachyphylaxis limits durability. Our recommendation is “conditional” because the underlying evidence is modest and patient responses are heterogeneous, but it formalizes what many clinicians already do: start with metoclopramide (lowest effective dose, limited duration, counsel on neurologic adverse effects) and reserve erythromycin for targeted use (exacerbations, bridging).
Several agents, including domperidone and prucalopride, received recommendations against first-line use. How will that influence discussions with patients who ask about these therapies?
Dr. Staller: Two points I share with patients: evidence and access/safety. For domperidone, the data quality is mixed, and US access is through an FDA IND mechanism; you’re committing patients to EKG monitoring and a non-trivial administrative lift. For prucalopride, the gastroparesis-specific evidence isn’t strong enough yet to justify first-line use. So, our stance is not “never,” it’s just “not first.” If someone fails or cannot tolerate initial therapy, we can revisit these options through shared decision-making, setting expectations about benefit, monitoring, and off-label use. The guideline language helps clinicians have a transparent, evidence-based conversation at the first visit.
The guidelines suggest reserving procedures like G-POEM and gastric electrical stimulation for refractory cases. In your practice, how do you decide when a patient is “refractory” to medical therapy?
Dr. Staller: I define “refractory” with three anchors.
1. Adequate trials of foundational care: dietary optimization and glycemic control; an antiemetic; and at least one prokinetic at appropriate dose/duration (with intolerance documented if stopped early).
2. Persistent, function-limiting symptoms: ongoing nausea/vomiting, weight loss, dehydration, ER visits/hospitalizations, or malnutrition despite the above—ideally tracked with a validated instrument (e.g., GCSI) plus nutritional metrics.
3. Objective correlation: delayed emptying on a standardized 4-hour solid-meal study that aligns with the clinical picture (and medications that slow emptying addressed).
At that point, referral to a center with procedural expertise for G-POEM or consideration of gastric electrical stimulation becomes appropriate, with multidisciplinary evaluation (GI, nutrition, psychology, and, when needed, surgery).
What role do you see dietary modification and glycemic control playing alongside pharmacologic therapy in light of these recommendations?
Dr. Staller: They’re the bedrock. A small-particle, lower-fat, calorie-dense diet—often leaning on nutrient-rich liquids—can meaningfully reduce symptom burden. Partnering with dietitians early pays dividends. For diabetes, tighter glycemic control can improve gastric emptying and symptoms; I explicitly review medications that can slow emptying (e.g., opioids; consider timing/necessity of GLP-1 receptor agonists) and encourage continuous glucose monitor-informed adjustments. Pharmacotherapy sits on top of those pillars; without them, medications will likely underperform.
The guideline notes “considerable unmet need” in gastroparesis treatment. Where do you think future therapies or research are most urgently needed?
Dr. Staller: I see three major areas.
1. Truly durable prokinetics: agents that improve emptying and symptoms over months, with better safety than legacy options (e.g., next-gen motilin/ghrelin agonists, better-studied 5-HT4 strategies).
2. Endotyping and biomarkers: we need to stop treating all gastroparesis as one disease. Clinical, physiologic, and microbiome/omic signatures that predict who benefits from which therapy (drug vs G-POEM vs GES) would transform care.
3. Patient-centered trials: larger, longer RCTs that prioritize validated symptom and quality-of-life outcomes, include nutritional endpoints, and reflect real-world medication confounders.
Our guideline intentionally highlights these gaps to hopefully catalyze better trials and smarter referral pathways.
Dr. Staller is with the Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston.